Figure 6

RocA suppresses in vivo tumor growth in a xenograft model. Subcutaneously established AsPC-1 cell-derived tumors in SCID mice were treated with the vehicle (1% DMSO in olive oil, n = 6) or RocA (5.0 mg/kg, n = 5) via daily intraperitoneal injection for 48 days. The tumor volume (A, B) and body weight (C) were monitored twice per week for 28 days. Values are the means ± SD of triplicate samples, *P < 0.01. Scale bar, 1 cm. D. Survival of mice with established tumor burden randomized to receive RocA or vehicle by intraperitoneal injection. E. Median survival of the mice in (D). Statistical significance was calculated by the log-rank test. Data are shown as the means ± SD. F. Histological analysis of tumors from (A, B) was performed by H&E staining and examining Ki-67 and cyclin D1 expression to compare cell proliferation in RocA- and vehicle-treated tumors. Scale bars, 50 μm. G. Quantification of Ki-67- and cyclin D1-positive cells in (F). Values are the means ± SD of triplicate samples, *P < 0.01.